Endocrine Therapy of Breast Cancer IV

Buch | Softcover

VII, 97 Seiten

2011 | 1. Softcover reprint of the original 1st ed. 1990
Springer Berlin (Verlag)
978-3-642-75950-5 (ISBN)

Artikel merken

The European School of Oncology came into existence to respond to a need for informa tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was. considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Univer sities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.

Role of Oestrogen and Progestin in Human Mammary Carcinogenesis.- Molecular Genetics of Steroid Hormone Receptors.- Prognostic Factors in Breast Cancer.- Prognostic Factors in Node-Negative Breast Cancer Patients.- Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer.- Tamoxifen as an Agonist for Metastatic Breast Cancer.- A Review of the International Experience with the LHRH Agonist Zoladex in the Treatment of Advanced Breast Cancer in Pre- and Perimenopausal Women.- Adjuvant Systemic Therapy in Node-Negative Breast Cancer.- Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients is Effective by Means Other than Ovarian Function Suppression.- Alternative Methods for Describing Treatment Benefit Including Quality-of-Life Considerations.

Erscheint lt. Verlag	13.12.2011
Reihe/Serie	ESO Monographs
Zusatzinfo	VII, 97 p.
Verlagsort	Berlin
Sprache	englisch
Maße	210 x 277 mm
Gewicht	291 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Gynäkologie / Geburtshilfe
	Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Schlagworte	Breast Cancer • Breast Cancer Chemotherapy • Cancer • Carcinogenesis • Cell • Chemotherapie • Chemotherapy • Endocrine Therapy • Endokrine Karzinigenese • Genetics • Hormone • hormone receptors • hormones • Hormonrezeptoren • molecular genetics • Oncology • Ovarsuppression • Steroid • Systemic Therapy
ISBN-10	3-642-75950-5 / 3642759505
ISBN-13	978-3-642-75950-5 / 9783642759505
Zustand	Neuware